Triple-negative breast cancer (TNBC) is one type of the most aggressive breast cancers with poor prognosis. It is of great urgency to develop new therapeutics for treating TNBC. Based on current treatment guideline and genetic information of TNBC, a combinational therapy platform integrating chemotherapy drugs and mRNA encoding tumor suppressor proteins may become an efficacious strategy. In this study, we developed paclitaxel amino lipid (PAL) derived nanoparticles (NPs) to incorporate both chemotherapy drugs and P53 mRNA. The PAL P53 mRNA NPs showed superior properties compared to Abraxane ® and Lipusu ® used in the clinic including high paclitaxel loading capacity (24 wt.%, calculated by paclitaxel in PAL), PAL encapsulation efficiency (94.7% ± 6.8%) and mRNA encapsulation efficiency (88.7% ± 0.7%). Meanwhile, these NPs displayed synergetic cytotoxicity of paclitaxel and P53 mRNA in cultured TNBC cells. More importantly, we demonstrated in vivo anti-tumor efficacy of PAL P53 mRNA NPs in an orthotopic TNBC mouse model. Overall, these chemotherapy drugs derived mRNA NPs provide a new platform to integrate chemotherapy and personalized medicine using tumor genetic information, and therefore represent a promising approach for TNBC treatment.
Introduction
Triple-negative breast cancer (TNBC) has been defined as a subtype of breast cancer with low expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2) [1] . Because TNBC lacks the therapeutic targets mentioned above, these tumors progress aggressively and lead to poor treatment outcome for TNBC patients [2, 3] . Consequently, there is an urgent demand to develop effective therapeutics for treating TNBC. Previous studies reported that combinational therapy improved therapeutic efficacy in comparison to single medicine, which provided a potential treatment strategy for hard-to-treat cancers [4, 5] , such as TNBC [6] . Currently, chemotherapy drugs are the main regimens in the systemic treatment guideline for TNBC [2] . Meanwhile, our understanding of tumorigenesis and relevant genetic information of TNBC establish the opportunity for personalized medicine [7] . According to previous tumor genetics studies on TNBC, mutation of tumor suppressor gene (TSG) TP53 was found in single most high rate (50%-80%) in TNBC patients' samples [8] . The wild type P53 protein suppresses aberrant cell cycles and assists apoptosis [9] while the mutant P53 protein fails to induce such responses [10] . Based on the characteristics of TNBC, we hypothesized that a combinational therapy combining chemotherapy drugs and personalized medicine based on genetic information may construct an effective platform for TNBC treatment.
To test this concept, we first synthesized chemotherapy drugs derived amino lipids (Fig. 1) . Then, we formulated these lipids with P53 mRNA to afford a nanoparticle platform integrating both chemotherapy drugs and personalized medicine. This platform holds several favorable features. For example, chemotherapy drugs can be fine-tuned if TNBC is sensitive to a specific drug. Moreover, in the case that other tumor suppressor gene is identified for a TNBC patient population, the platform is capable of delivering mRNA encoding that particular TSG. Furthermore, mRNA transcripts introduce transient translation in the cytoplasm that avoids the risk of insertional mutagenesis in the genome [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . Encouraged by previous research findings in Ref. [17] , we designed and prepared chemotherapy drugs derived lipid conjugates containing ionizable amino groups. In addition to their mRNA encapsulation ability, these drug-lipid conjugates can also potentially increase the apparent solubility of water-insoluble drugs [29] as well as drug loading capacity when formulated into nanoparticles [30] . Because chemotherapy drugs derived amino lipids have strong interactions with mRNA, these nanoparticles are able to simultaneously deliver these two types of therapeutics to the same tumor cells, resulting in optimal combinational effects.
Consistent with our design, we found the formulated paclitaxel amino lipid (PAL) P53 mRNA nanoparticles (NPs) exhibited high paclitaxel loading capacity (24 wt.%), which is higher than that of two clinically used paclitaxel formulations, Abraxane ® (paclitaxel, ~ 10 wt.%) [31] , an albumin bonded paclitaxel, and Lipusu ® (paclitaxel, ~ 7 wt.%) [32] , a liposomal paclitaxel nanoparticle. Other favorable characteristics included its high paclitaxel encapsulation efficiency (94.7% ± 6.8%) and high mRNA encapsulation efficiency (88.7% ± 0.7%). These PAL mRNA NPs were capable of loading different kinds of mRNAs and expressing functional protein in MDA-MB-231 cells, a human TNBC cell line. Moreover, the PAL P53 mRNA NPs showed significant anti-tumor efficacy in an orthotopic TNBC mouse model. This proof-of-concept study supports the rationale of a nanoparticles platform combining chemotherapy drugs and mRNAs encoding tumor suppressor proteins as a potential treatment for TNBC.
Results

Synthesis of chemotherapy drugs derived amino lipids
First, we selected two representative anti-breast cancer agents, paclitaxel and camptothecin [33, 34] . As shown in Fig. 1(a) , we installed amino lipid on paclitaxel and camptothecin, respectively through an ester bond. These two compounds were named PAL and camptothecin amino lipid (CAL). PAL and CAL shared the same lipid chains which contained two tertiary amines that could be ionized at acidic pH environment and interact with mRNA molecules ( 
Characterization of chemotherapy drugs derived mRNA nanoparticles
Next, we formulated either PAL or CAL with 1,2-dioleoylsnglycero-3-phosphoethanolamine (DOPE), cholesterol (Chol), 1,2-dimyristoyl-rac-glycero-3-methylpolyoxyethylene (DMG-PEG2000, PEG) (molar ratio: conjugate/DOPE/Chol/DMG-PEG2000 = 20/30/ 40/0.75), and a non-toxic control mRNA (ctrl mRNA) to prepare the nanoparticles as reported previously [35] [36] [37] . PAL and CAL mRNA NPs have similar particle properties including the size distribution and zeta potential (Fig. S2 in the ESM) . In order to compare the cytotoxicity of these two NPs, we performed an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in MDA-MB-231 cells, a human TNBC cell line. As shown in Fig. 1(b) , PAL ctrl mRNA NPs were more potent (IC50 = 0.35 μM) than CAL ctrl mRNA NPs (IC50 = 1.00 μM). In addition, we studied the mRNA delivery efficiency of PAL and CAL mRNA NPs using GFP mRNA. To minimize the effects of cytotoxicity in affecting the results of flow cytometry, we treated MDA-MB-231 cells only 6 h and then green fluorescent protein (GFP) signals were measured by a flow cytometer. The results showed PAL GFP mRNA NPs also induced a significantly higher GFP signal compared with that in CAL GFP mRNA NPs ( Fig. 1(c) ). Thus, we chose PAL mRNA NPs for further formulation optimization.
Formulation optimization of chemotherapy drugs derived mRNA nanoparticles
We further optimized the PAL mRNA NPs by using an experimental orthogonal design to study the effects of each formulation components on mRNA delivery efficiency, including PAL, DOPE, Chol, and DMG-PEG2000 ( Fig. 2(a) ) [35] . An L16(4 4 ) orthogonal array was generated, and 16 different formulations were prepared and characterized according to this array (Table S1 and (Table S1 in the ESM), we increased the PEG molar ratio and adjusted the formulation to PAL/DOPE/Chol/DMG-PEG2000 = 30/50/40/0.75 (formulation 17). The GFP signal of optimized formulation 17 was comparable to formulation 16, the highest one in the orthogonal array (Fig. S4 in the ESM). Thus, formulation 17 was used for the following studies.
Then, we prepared the nanoparticles using P53 mRNA with a FLAG tag sequence ( Fig. S5(a) in the ESM) and evaluated its delivery in vitro. The optimized PAL P53 mRNA NPs formulation showed a relatively homogeneous peak in size distribution ( Fig. 2(f) ). PAL P53 mRNA NPs were in spherical morphology from the cryogenic electron microscopy (cryo-EM) image ( Fig. 2(g) ). After treatment of cells with PAL P53 mRNA NPs, we stained the cells via antibody against the FLAG tag. The green signal in Fig. 2 (h) indicated apparent expression of P53 protein in these cells. We prepared PAL P53 mRNA NPs from different batches and observed similar fluorescence signal after P53 mRNA NPs treatment, demonstrating the reproducibility of these nanoparticles ( The stability test showed the FLAG signal were consistent after treatment with PAL P53 mRNA NPs stored at 4 °C for at least one week, which indicated that these nanoparticles were stable under the storage condition ( Fig. S5(c) in the ESM). Similar results were noticed for particle size and its distribution ( 
In vitro cytotoxicity of chemotherapy drugs derived mRNA nanoparticles
Before we tested the cytotoxic effect of PAL P53 mRNA NPs, we studied the TP53 mutation status of these MDA-MB-231 cells. The results showed a single nucleotide mutation from G to A (Fig. S6 in the ESM), which caused the corresponding amino acid change from arginine to lysine (R280K). This genetic mutation is same as that in Ref. [38] . Then, cytotoxicity of PAL P53 mRNA NPs were examined by the MTT assay in these cells. To study the combinatorial effects of paclitaxel (PTX) and P53 mRNA, we synthesized a control lipid without drug conjugate, amino lipid (AL, Fig. S1 (a) in the ESM). Also, we included a non-toxic mRNA as a control for P53 mRNA (ctrl mRNA). Then, we formulated these four types of nanoparticles: AL ctrl mRNA NPs (PTX−, P53−), AL P53 mRNA NPs (PTX−, P53+), PAL ctrl mRNA NPs (PTX+, P53−) and PAL P53 mRNA NPs (PTX+, P53+). All these NPs shared similar characteristics (Figs. S7(a) and S7(b) in the ESM). As shown in Fig. 3(a) , the cytotoxicity was in a dose-dependent manner. AL ctrl mRNA NPs showed minimum toxicity, while AL P53 mRNA NPs increased cytotoxicity at high doses of P53. Although both PAL ctrl mRNA NPs and PAL P53 mRNA NPs displayed dramatic inhibition of tumor cell growth, PAL P53 mRNA NPs were more active than PAL ctrl mRNA NPs (p < 0.001 at an mRNA dose of 63 ng per well and p < 0.05 at an mRNA dose of 125 ng per well). We also calculated the combination index (CI = 0.937 < 1) from the data of PAL ctrl mRNA NPs (PTX+, P53−), AL P53 mRNA NPs (PTX−, P53+), and PAL P53 mRNA NPs (PTX+, P53+), which indicated a synergetic effect between paclitaxel and P53 mRNA. Meanwhile, we measured the PTX encapsulation efficiency and release profile of PAL P53 mRNA NPs. Quantitative results gave a 94.7% ± 6.8% of PTX encapsulation efficiency in the PAL P53 mRNA NPs (Fig. S7(c) in the ESM). At the 48-and 72-hour time points, around 37% and 84%, respectively of PAL was released ( Fig. 3(b) ).
In vivo anti-tumor efficacy of chemotherapy drugs derived mRNA nanoparticles
Given the encouraging in vitro results of PAL P53 mRNA NPs, we established an orthotopic TNBC model in nude mice to test its in vivo anti-tumor activity. Five groups (n = 8) were included: phosphate buffered saline (PBS) control group (PBS), free P53 mRNA group (P53 mRNA), free PTX treatment group (PTX), PAL ctrl mRNA NPs treatment group (PAL ctrl mRNA NPs), and PAL P53 mRNA NPs treatment group (PAL P53 mRNA NPs). Tumor size was measured every day after the first treatment. Since several mice in the PBS group (4 mice) and free P53 mRNA group (3 mice) reached the end points at the day 13 after treatment, Fig. 4(a) was plotted till day 12 with at least 7 mice in each group. PAL P53 mRNA NPs showed significantly stronger inhibition of tumor growth in comparison to other groups (Fig. 4(a) ). Specifically, one mouse in PAL P53 mRNA NPs group (mouse 779) showed complete tumor elimination after treatments, which was confirmed by observation, touching and in vivo imaging of luciferase signal (Fig. S8 in the ESM) . More importantly, the Kaplan-Meier survival curves showed PAL P53 mRNA NPs treatment significantly extended the median survival time of tumor bearing mice compared to other four groups (Fig. 4(b) ). PAL ctrl mRNA NPs and PTX free drug treatment groups exhibited tumor inhibition to some extent, and their efficacy was much weaker than that of PAL P53 mRNA NPs treatment group. Obvious FLAG signal in the dissected tumor tissue was noticed in consistent with the in vitro imaging, suggesting the expression of P53 proteins in tumors (Fig. 4(c) ). The body weight of mice from all five groups were comparable (Fig. S9 in the ESM) .
Conclusion
In summary, we aim to test the hypothesis that a combination of chemotherapy drugs and personalized medicine may offer a superior strategy for treating TNBC. On one hand, chemotherapy drugs are widely used small molecule anti-tumor agents for TNBC. On the other hand, personalized medicine is based on the analysis of genetic information from TNBC patients [8] . For example, a large percentage of TNBC patients possesses P53 loss or mutation. To prove this concept, we designed and developed a PAL P53 mRNA nanoparticles (PAL P53 mRNA NPs). PTX was used as a chemotherapy drug in the current TNBC treatment guideline [2] . PTX has low water solubility and the most widely used formulation Taxol ® uses Cremophor EL ® and ethanol to increase the solubility of PTX in water [31] . However, the formulation vehicle Cremophor EL ® was known to cause unfavorable hypersensitivity, which required the patients to take premedication [39] . We formulated the paclitaxel in the newly synthesized PAL with other formulation components: DOPE, Chol, and DMG-PEG2000 to encapsulate mRNA molecules and prepare PAL P53 mRNA NPs. The formulation composition was optimized by an orthogonal array to maximize its mRNA delivery efficiency. The optimized formulation was stable for at least one week under 4 °C. Moreover, the high PTX loading capacity (24 wt.%), PTX encapsulation efficiency (94.7% ± 6.8%) and extended drug release profile were favorable for in vivo applications. When we incorporated P53 mRNA in the optimized formulation and treated it with MDA-MB-231 cells, PAL P53 mRNA NPs showed synergetic cytotoxicity from its two types of therapeutic components: PTX and P53 mRNA. In addition to the promising in vitro anti-tumor activity, PAL P53 mRNA NPs (equivalent to 10 mg/kg PTX, 2 mg/kg P53 mRNA) induced strong therapeutic efficacy by inhibiting tumor growth and extending the overall survival of tumor bearing mice. In conclusion, this proof-of-concept study demonstrated that this nanoparticle platform combining chemotherapy drugs and tumor genetic information merit further development for TNBC therapy. Such a nanomaterial platform is applicable to the broad category of chemotherapy drugs and tumor suppressor genes for treating other types of cancers.
Materials and methods
Materials
All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA) unless otherwise specified. Paclitaxel and camptothecin were purchased from Medkoo Biosciences (Morrisville, NC, USA). DOPE was purchased from Avanti Polar Lipids, Inc (Alabaster, AL, USA). DMG-PEG2000 was purchased from NOF America Corporation (White Plains, NY, USA). The human MDA-MB-231-luc (MDA-MB-231) cells were the kind gift from Dr. Peixuan Guo's lab, and were cultured in DMEM/F12 culture medium containing 10% fetal bovine serum (FBS). MTT was purchased from Amresco (Solon, OH, USA). Anti-FLAG primary antibody (ab-1162) and fluorescein isothiocyanate (FITC) labeled secondary antibody (ab-6717) were purchased from Abcam (Cambridge, MA, USA). DNA extraction (DNeasy ® ) and purification (QIAquick ® ) kits were purchased from QIAGEN (Germantown, MD, USA). P53 primers were ordered from Eurofins Genomics, LLC (Louisville, KY, USA). Animal experiments were approved by the Ohio State University Institutional Animal Care and Use Committee (IACUC).
Synthesis of control lipids and chemotherapy drugs derived amino lipids
Synthesis of AL
Compounds b and c were synthesized according to methods reported previously [35, 40] . A solution of compound c (500 mg, 1.58 mmol) in CH2Cl2 (2 mL) was added excess amount of trifluoroacetic acid (2 mL). The mixture was stirred at room temperature (RT) for 2 h and monitored with thin layer chromatography. Upon completion of the reaction, the solvent was evaporated to yield oil like intermediate. The intermediate was dissolved in 20 mL of anhydrous tetrahydrofuran, followed by adding triethylamine (0.5 mL). The resulting mixture was stirred for 30 min at RT. After adding dodecyl aldehyde (1.5 g, 7.9 mmol) and NaBH(OAc)3 (1.7 g, 7.9 mmol), the reaction mixture was stirred at RT for 24 h. After the solvent was removed, the residue was purified by column chromatography using a CombiFlash Rf system with a RediSep Gold Resolution silica column (Teledyne Isco) with gradient elution (CH2Cl2 and ultra) from 100% CH2Cl2 to 70% CH2Cl2 (ultra, CH2Cl2/MeOH/NH4OH = 75/22/3 by volume) to give 400 mg AL, yield 35%. 
Synthesis of PAL
AL (250 mg, 0.35 mmol) was dissolved in 1.5 mL tetrahydrofuran (THF) and 1.5 mL MeOH, followed by adding 1.5 mL NaOH aqueous (1 M). The reaction mixture was stirred at 70 °C for 3 h. After adding 100 mL CH2Cl2, the mixture was dried with MgSO4. After the solvent was removed, the residue was dissolved in 10 mL anhydrous CH2Cl2. To the solution was added paclitaxel (296 mg, 0.35 mmol), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) (80 mg, 0.42 mmole) and N,N'-dimethyl-1,3-propanediamine (DMPA) (10 mg, 0.08 mmol). The resulting mixture was stirred at RT overnight. After the solvent was removed, the residue was purified by column chromatography using a CombiFlash Rf system with a RediSep Gold Resolution silica column (Teledyne Isco) with gradient elution (CH2Cl2 and ultra) from 100% CH2Cl2 to 75% CH2Cl2 (ultra, CH2Cl2/MeOH/NH4OH = 75/22/3 by volume) to give 275 mg PAL, yield 52%. (3H, s), 1.76 (1H, s), 1.71 (3H, s), 1.64-1.58 (5H, m), 1.43-1.42 (10H,  m), 1.28 (57H, s), 1.16 (3H, s) , 0.92-0.88 (9H, t, J = 8). MS (m/z): [M+H] + calcd. for C92H142N3O15, 1,529.0433; found, 1,529.0320.
Synthesis of CAL
AL (250 mg, 0.35 mmol) was dissolved in 1.5 mL THF and 1.5 mL MeOH, followed by adding 1.5 mL NaOH aqueous (1 M). The reaction mixture was stirred at 70 °C for 3 h. After adding 100 mL CH2Cl2, the mixture was dried with MgSO4. After the solvent was removed, the residue was dissolved in 10 mL dry CH2Cl2. To the solution was added paclitaxel (121 mg, 0.35 mmol), EDC (80 mg, 0.42 mmol) and DMPA (10 mg, 0.08 mmol). The resulting mixture was stirred at RT overnight. After the solvent was removed, the residue was purified by column chromatography using a CombiFlash Rf system with a RediSep Gold Resolution silica column (Teledyne Isco) with gradient elution (CH2Cl2 and ultra) from 100% CH2Cl2 to 75% CH2Cl2 (ultra, CH2Cl2/MeOH/NH4OH = 75/22/3 by volume) to give 50 mg CAL, yield 14%. 
Characterization of P53 mutation status in MDA-
MB-231 cells
To check the P53 mutation status of our MDA-MB-231 cells, genomic DNA was extracted from cells using a DNA extraction kit (DNeasy ® , QIAGEN, MD, USA). Polymerase chain reaction (PCR) was applied to amplify a 596bp length of genomic DNA across the reported mutation position within the P53 region in MDA-MB-231 cells. The forward primer used was 5'-GGGACCTCTTAACCTGTGGC-3' , and the reverse primer was 5'-TCTTTGAGGCATCACTGCCC-3' . After purification, the sequence was determined by Sanger sequencing.
Preparation of P53 mRNA
The cDNA sequence encoding wild-type P53 of 393 amino acids was obtained from Ensembl (transcript ID: ENST00000269305.8).
A fragment sequence coding a FLAG tag (GACTACAAGGACG ACGATGACAAG) and GS linker (ggatcc) was added to the 5' of P53 coding sequence [41] . The corresponding linear dsDNA template was ordered from IDT as a gBlock gene fragment and subsequently inserted into a pUC19 derived vector via Golden Gate assembly. The resulting plasmid was amplified by PCR to generate the DNA template for transcription. The uncapped mRNA encoding P53 was synthesized in vitro using AmpliScribe T7-Flash Transcription Kit (Lucigen) and purified with RNA Clean & Concentrator-25 (Zymo), following manufacturers' instructions. Cap-1 structure was added using the Vaccinia Capping System and Cap 2´-O-Methyltransferase (NEB). After determination of concentration by Nanodrop (Thermo), the mRNA was stored in 1×TE at −80 °C until use.
The length of the final P53 mRNA product was examined by running precast 0.8% agarose E-gel electrophoresis (Invitrogen).
P53 mRNA was mixed with equal volume of denaturing loading buffer (8.1 M urea, 0.9 mM EDTA, 0.1% (m/v) xylene cyanol FF, 0.1% (m/v) bromophenol blue in 1×TBE) and ssRNA ladder (NEB) with 4× volume of RNA loading dye (NEB). Both P53 mRNA and ssRNA ladder were incubated at 90 °C for 90 s right before gel loading. After electrophoresis, image was taken in ChemDoc MP imaging system (Bio-Rad).
Preparation, optimization and characterization of mRNA NPs
The mRNA nanoparticles used in vitro were prepared by the pipetting method [35] [36] [37] 42] . The mRNA nanoparticles used in vivo were prepared using microfluidic device (Precision NanoSystems, Vancouver, BC, Canada). For both methods, the lipid compounds were dissolved in ethanol to the desired concentration, and mRNA was diluted in the citrate buffer (pH = 3). After well pipetting and mixing with the lipid compounds and mRNA solution, the mRNA nanoparticles were prepared. For in vivo use, we dialyze the freshly formulated mRNA nanoparticles in the PBS solution before intravenous (i.v.) injection. The size distribution and zeta potential of mRNA nanoparticles in water were determined by Zetasizer (Malvern, Westborough, MA, USA). mRNA encapsulation efficiency (EE%) was determined by RiboGreen assay [35] .
To optimize the formulation, an L16( 4 4 ) orthogonal array was generated (Table S1 in the ESM). 16 formulations were first prepared according to the orthogonal array, and their size, PDI and zeta potential were measured. Next, these formulations each encapsulating 100 ng GFP mRNA was added to MDA-MB-231 cells in a 24 wells plate for 6 h. The GFP intensity was then analyzed by a flow cytometer (LSR II, BD) and used to analyze the effects of formulation components.
PTX loading capacity was calculated by the following equation: PTX loading capacity % = (weight of equivalent PTX in formulated PAL P53 mRNA NPs)/(weight of all lipid materials (PAL + DOPE + Chol + DMG-PEG2000) in formulated PAL P53 mRNA NPs) × 100%. PTX EE% was determined by mass spectrum quantification of PAL. PTX EE% = (amount of PAL after dialysis)/(amount of total PAL added) × 100%. Chloroform was added to breakdown and extract PAL from PAL P53 mRNA NPs. The organic phase was then separated with water phase by centrifuge at 14,000 g for 15 min. Next, the chloroform phase was transferred and mixed with methanol (chloroform:methanol=1:9, v/v) for MS quantification. The standard curve was established for quantification of PAL in paclitaxel encapsulation efficiency test (Fig. S7(c) in the ESM). Cryo-EM image was obtained using the same method as reported before [35] . Briefly, CryoTEM samples were prepared by applying a small aliquot (3 μL) of PAL P53 mRNA NPs to a specimen grid. After blotting away excess liquid, the grid was immediately plunged into liquid ethane to rapidly form a thin film of amorphous ice using Vitrobot Mark IV system (Thermo Fisher Scientific, Hillsboro). CryoTEM images were collected at a nominal magnification of 57,000× with Falcon direct electron detector on Thermo Scientific TM Glacios TM CryoTEM. The microscope was operated at an acceleration voltage of 200 kV. PTX release was determined by mass spectrum quantification of remaining PAL in the release solution at different time points. The release solution contained 0.5 mg/mL esterase in 0.1% Tween 20 PBS. After incubating mRNA nanoparticles in release solution for 3, 9, 24, 48, 72 h at 37 °C, 200 rpm, chloroform was added to breakdown and extract remaining PAL. The organic phase was then separated and tested following the same method used in paclitaxel encapsulation efficiency test.
In vitro delivery of P53 mRNA NPs in MDA-MB-231 cells
To test the delivery of P53 mRNA NPs in cells, the FLAG tag was labeled and observed by an immunofluorescence experiment. Briefly, after 6 hours' incubation with P53 mRNA NPs, the cells were fixed with 4% paraformaldehyde and permeabilized with 0.4% Triton and followed by blocking with 1% bovine serum albumin (BSA) in phosphate buffered saline with Tween-20 (PBST). The FLAG tag was then labeled by anti-FLAG primary antibody (Abcam, ab-1162, 1:100 dilution) and FITC labeled secondary antibody (Abcam, ab-6717, 1:1,000 dilution). The nucleus was labeled with Hoechst 33342. The FITC and Hoechst 33342 signals were observed by a fluorescent microscope (Nikon, Japan). Stability of 4 °C stored mRNA nanoparticles was determined by measuring the size and distribution, and by detecting P53 protein using an immunofluorescence experiment at different time points.
In vitro cytotoxicity of chemotherapy drugs derived mRNA NPs
The cytotoxicity of different mRNA NPs was determined by MTT assay. 2,000 cells were seeded in 96 wells plate 24 h before adding different formulations. After 48 h incubation with free drug or mRNA nanoparticles, MTT was added. After another 4 h incubation, dimethyl sulfoxide (DMSO) was added to dissolve purple formazan, and the absorbance (Ab) was read at 570 nm in plate reader (MolecularDevices Spectramax M5, San Jose, CA, USA). The cell viability (%) = (Abtreatment − Abblank)/ (Abuntreated control − Abblank) × 100%. The synergetic effect was calculated and analyzed by Compusyn. The absolute IC50 values were calculated by GraphPad Prism 6 (La Jolla, CA, USA).
In vivo anti-tumor efficacy studies
All animal experiments were performed in accordance with the Guidelines for Care and Use of Laboratory Animals of The Ohio State University and were approved by the Animal Ethics Committee of Institutional Animal Care and Use Committee (IACUC). 2 × 10 6 MDA-MB-231-luc cells in 50 μL PBS were injected in the #4 abdominal mammary gland of athymic nude female mice. Mice were randomly grouped (n = 8 in each group) when the tumor reached around 30 mm 3 . Treatment with 10 mg/kg PTX or mRNA NPs (2 mg/kg mRNA) at an equivalent PTX dose was given twice a week intravenously for three weeks. Censoring of one mouse occurred in PAL ctrl mRNA NPs group on day 7 after tumor inoculation, therefore n = 7 in PAL ctrl mRNA NPs group from day 8, and n = 8 in other groups. Tumor volume was checked by digital caliper every day. Removal criteria for the tumor bearing mice were either length of tumor longer than 1.6 cm, body factor smaller than 2 or moistness or seeping in the ulceration area shown on tumor. Mice body weight was measured before each treatment during the 6 dosages. The tumor volume = length × (width) 2 /2. PTX was first dissolved in Cremophor ® EL/ethanol (50:50, v/v) and then diluted in PBS. To image P53 protein in vivo, tumor tissue was dissected 24 h after the last dose of PAL P53 mRNA NPs and fixed in 4% paraformaldehyde. After fixation, the tumor tissue was immersed in 30% sucrose solution overnight. The 8 μm tumor section was then prepared using the cryostat section method. Finally, the FLAG tag and nucleus were labeled and imaged using same methods mentioned above.
Statistical analysis
All statistical analyses were conducted on R3.4.3 (The R Foundation). Student's t tests were used to analyze in vitro data; the in vivo efficacy data were analyzed using two-way ANOVA with repeated measurements; the survival of tumor bearing mice was analyzed using log rank tests. All tests were two-tailed and p < 0.05 was considered statistically significant.
